Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
18 slides from Teva Pharmaceutical Industries's conference presentation, Jan 8, 2024
Slide 1: 42nd Annual J.P. Morgan Healthcare Conference
Teva Pharmaceutical Industries Ltd. 42 Annual nd J.P. Morgan Healthcare Conference January 8, 2024
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our futu
Slide 3: President and Chief Executive Officer
President and Chief Executive Officer
Slide 4: Where We Are Today
Where We Are Today Pivot to Growth Strategy launched in May 2023 From historical negative topline evolution Back to revenue growth AUSTEDO® is an established growth driver; Limited focus on our growth assets and Innovative pipeline externally recognized, pipeline in light of recent business developm
Slide 5: Significant progress on all pillars
Significant progress on all pillars Deliver on Step up Sustain generics Focus our growth engines innovation powerhouse business • AUSTEDO - AUSTEDO XR • Late-stage pipeline • Generics back to revenue • Teva API launched; on track to • Anti-TL1A collaboration growth as of Sept. 2023 • Executing on st
Slide 6: 2023 strategy execution
2023 strategy execution Long-Term • On track to reach $1.2B 2023 sales Goal to achieve >$2.5B target revenue by 2027 across tardive • Launched improved profile with once- dyskinesia and chorea associated daily XR in May 2023 with Huntington's disease • Launched in May 2023 Establish a differentiated
Slide 7: U.S. and global revenues, Jan.-Sept. 2022 vs 2023
$ millions, U.S. revenues $ millions, global revenues +32% 817 +24% 618 314 254 Jan.-Sept. Jan.-Sept. Jan.-Sept. Jan.-Sept. 2022 2023 2022 2023 7|
Slide 8: Proven capabilities, strong late-stage biosimilar pipeline
Proven capabilities Strong late-stage pipeline 2022 U.S. Biosimilar Global commercial reach Reference originator Geographic development product brand net scope2 status revenue Generated global revenue >$1B through its biosimilar franchise since launch Filed1 ~$19B Moving Ahead Filed ~$6B 16 assets i
Slide 9: Innovative pipeline by phase
Phase I Phase II Phase III Anti-IL15 (‘408) Anti-TL1A (‘574) LAI olanzapine (‘749) Celiac Disease IBD (UC/CD) Schizophrenia Anti-PAR2 (‘192) ICS/SABA (‘248) Neuroscience Asthma Anle138b1 (‘286) Therapeutic areas: MSA Neuroscience Respiratory Immunology Select assets as of November 2023 IBD: Inflamma
Slide 10: Olanzapine LAI, ICS/SABA, anti-TL1A market potential and progress
Potential Market Size 3 Progress in 2023 Collaboration with Royalty Olanzapine LAI Potential to be first long-acting Pharma (TEV-‘749) olanzapine with a favorable $4B Phase III recruitment finalized; safety profile read-out now expected in H2 H2 2024 – Phase III results '24 (vs. H1 ‘25) ICS/SABA Pot
Slide 11: Financing and building our innovative pipeline
Financing and building our innovative pipeline Anti-TL1A • Maximizing asset value to Teva with pipeline-in-a-product potential Up to $1.5B • 50/50 development cost and profit sharing cash Olanzapine LAI • Royalty Pharma to provide R&D funding for the development of olanzapine Up to $125M LAI (TEV-‘7
Slide 12: Making our Generics Business a Sustainable Powerhouse
Making our Generics Global commercial footprint with focused portfolio Business a • Concentrate on high value products and best-in-class service level • Exit lowest contribution products Sustainable Powerhouse Focused pipeline • High-value segments, U.S. and EU first to market, complex technologies
Slide 13: Complex generic products approved and planned launches
Planned complex generic launches in 10 New complex generic products approved in '22-’23 13 '24-'25, with a combined brand value of approximately $10B Select complex portfolio and pipeline products Respiratory Inhalers Long-Acting Injectables Peptides Ophthalmic Products Other technologies • Budesoni
Slide 14: Teva API opportunity
Strong market potential Teva API best prepared to seize opportunity Highly profitable business Industry leading small molecule API portfolio ~350 APIs in the portfolio, including complex molecules ~$85B merchant market for Large and diversified 3rd party customer base small molecules* ~1,000 custome
Slide 15: Healthy Future
15] Healthy Future Teva Sustainability Framework Healthy Future Our Purpose in Practice ne Healthy People Healthy Planet Healthy Business Improving the well-being Safeguarding Leading our business. of people and society our planet the right way Access to Medicines & Healthcare Climate Action & Resil
Slide 16: Financial targets
Revenue growth Operating Net debt/ Cash-to- (CAGR) income margin1, 2 adjusted EBITDA2 earnings2, 3, 4 Mid-single 30% 2.0x 80% digit 1. Operating income margin = Non-GAAP operating income divided by net revenues; excluding potential impact of BD depending on timing 2. All measures including operating
Slide 17: Return to growth, sustain growth, accelerate growth
2028+ 2025-2027 2023-2024 Sustain growth • Innovative launches Accelerate growth (anti-TL1A, anti-PD1-IL2, anti-IL15) Return to growth • Sustainable innovative pipeline • Innovative launches • AUSTEDO and AJOVY strong (olanzapine LAI, ICS/SABA) • Focused business development growth • Biosimilars gro
Slide 18: Slide 18
Teva Pharmaceutical Industries — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix